AcelRx Pharmaceuticals Inc  

(Public, NASDAQ:ACRX)   Watch this stock  
Find more results for PAMELA J. PALMER
3.38
+0.06 (1.81%)
Apr 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.27 - 3.40
52 week 2.59 - 5.88
Open 3.30
Vol / Avg. 150,334.00/324,303.00
Mkt cap 155.92M
P/E     -
Div/yield     -
EPS -0.55
Shares 45.31M
Beta 2.01
Inst. own 69%
Jun 22, 2016
AcelRx Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 3:00PM EDT - Add to calendar
May 12, 2016
AcelRx Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference - 1:40PM EDT - Add to calendar
May 11, 2016
AcelRx Pharmaceuticals Inc at Biocentury BioEquity Europe - 5:00AM EDT - Add to calendar
May 2, 2016
Q1 2016 AcelRx Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Apr 5, 2016
AcelRx Pharmaceuticals Inc at EBD BIO-Europe Spring Conference
Mar 29, 2016
AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016 Corporate Call - Webcast
Mar 15, 2016
AcelRx Pharmaceuticals Inc at ROTH Conference - Webcast
Mar 9, 2016
AcelRx Pharmaceuticals Inc at Cowen Health Care Conference - Webcast
Mar 7, 2016
Q4 2015 AcelRx Pharmaceuticals Inc Earnings Call - Webcast
Mar 7, 2016
Q4 2015 AcelRx Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -609.60% -126.66%
Operating margin -435.61% -103.59%
EBITD margin - -89.36%
Return on average assets -32.62% -22.78%
Return on average equity -115.76% -61.17%
Employees 36 -
CDP Score - -

Address

351 Galveston Dr
REDWOOD CITY, CA 94063-4736
United States - Map
+1-650-2163500 (Phone)
+1-650-2166500 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

Officers and directors

Adrian Adams Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Richard A. King President
Age: 49
Bio & Compensation  - Reuters
Howard B. Rosen Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Timothy E. Morris Chief Financial Officer, Principal Accounting Officer
Age: 53
Bio & Compensation  - Reuters
Pamela P. Palmer M.D. Ph.D. Chief Medical Officer, Director
Age: 52
Bio & Compensation  - Reuters
Badri N. Dasu Chief Engineering Officer
Age: 52
Bio & Compensation  - Reuters
Lawrence G. Hamel Chief Development Officer
Age: 63
Bio & Compensation  - Reuters
Jane Wright-Mitchell Chief Legal Officer
Age: 46
Bio & Compensation  - Reuters
Richard F. Afable M.D. Director
Age: 61
Bio & Compensation  - Reuters
Mark G. Edwards Independent Director
Age: 57
Bio & Compensation  - Reuters